Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nimbus Technologies
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Nimbus has advanced four small molecule programs into the clinic, with prior assets demonstrating proof-of-concept (ACC sold to Gilead; TYK2 sold to Takeda). Current pipeline spans early to mid clinical stages (Phase 1/2) in oncology, immunology, and metabolic disease[2][3][4][5][6][8][11].
- Therapeutic areas
- ImmunologyGastroenterologyMetabolic DisordersDermatologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Takeda Pharmaceutical (sale/licensing of TYK2 asset)Gilead (sale/licensing of ACC asset)Eli Lilly (metabolic disease partnership, specifics undisclosed)[6]
Beyond the preview
Go deeper on Nimbus Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimbus Technologies.